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Abstract
Background: The neurotrophin Brain-Derived Neurotrophic Factor (BDNF) influences nigral dopaminergic neurons via
autocrine and paracrine mechanisms. The reduction of BDNF expression in Parkinson’s disease substantia nigra (SN)
might contribute to the death of dopaminergic neurons because inhibiting BDNF expression in the SN causes
parkinsonism in the rat. This study aimed to demonstrate that increasing BDNF expression in dopaminergic neurons of
rats with one week of 6-hydroxydopamine lesion recovers from parkinsonism. The plasmids phDAT-BDNF-flag and
phDAT-EGFP, coding for enhanced green fluorescent protein, were transfected using neurotensin (NTS)-polyplex, which
enables delivery of genes into the dopaminergic neurons via neurotensin-receptor type 1 (NTSR1) internalization.
Results: Two weeks after transfections, RT-PCR and immunofluorescence techniques showed that the residual
dopaminergic neurons retain NTSR1 expression and susceptibility to be transfected by the
NTS-polyplex. phDAT-BDNF-flag transfection did not increase dopaminergic neurons, but caused 7-fold increase
in dopamine fibers within the SN and 5-fold increase in innervation and dopamine levels in the striatum. These
neurotrophic effects were accompanied by a significant improvement in motor behavior.
Conclusions: NTS-polyplex-mediated BDNF overexpression in dopaminergic neurons has proven to be
effective to remit hemiparkinsonism in the rat. This BDNF gene therapy might be helpful in the early stage of
Parkinson’s disease.
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Background
The brain-derived neurotrophic factor (BDNF) is a mem-
ber of the neurotrophin family that is expressed by dopa-
mine (DA) neurons along with its high-affinity receptor
TrkB (tropomyosin related kinase B) [1, 2]. The expres-
sion of BDNF and TrkB during the prenatal and early
postnatal development is crucial for the induction of the
DA phenotype, determination of the number of mesen-
cephalic DA neurons, and the formation of synaptic con-
nectivity in the target innervation nuclei [3, 4]. In the
adult brain, BDNF promotes neuron survival and protec-
tion of nigral DA neurons against toxic insults [5–7].
Accordingly, inhibiting BDNF expression by antisense
oligonucleotide infusion causes loss of nigral DA neurons
and mimics parkinsonism in adult rats [8]. In Parkinson’s
disease (PD), the significant reduction of BDNF and
TrkB in the substantia nigra (SN) might contribute to
the death of DA neurons thus worsening the neurode-
generation [9–11]. Therefore, reinforcing BDNF expres-
sion in DA neurons might rescue the nigrostriatal DA
pathway from neurodegeneration.
To date, protective effects of BDNF have been shown in
animals using procedures that supply BDNF into the stri-
atum before the lesion. For instance, by infusion of BDNF
protein [12], grafts of fibroblasts or astrocytes genetically
engineered to produce BDNF [13, 14], or gene-therapy ap-
proaches using viral vectors [15]. Nevertheless, the deliv-
ery of BDNF into the striatum is inefficient to cause
restorative effects in chronic neurodegeneration due to
the scarcity of the nigrostriatal terminals, limiting its
retrograde transport to the nigral cell bodies [16, 17]
where is needed to provide neuron survival and stimulate
the synthesis of proteins for the growth of neurites and
axons [18]. The restorative effect of BDNF delivery into
the SN on degenerated nigrostriatal DA pathway remains
controversial. A study using human mesenchymal stem
cells epigenetically modified to secrete BDNF grafted in
the SN one week after the 6-hydroxydopamine (6-OHDA)
lesion causes significant hypertrophy of nigral DA neu-
rons, increase of striatal innervation and stabilization of
amphetamine-induced motor activity [19]. In contrast, a
study using an adeno-associated viral (AAV) vector to
transduce BDNF in the SN of hemiparkinsonian rats
showed no neurotrophic effects on DA neurons and stri-
atal innervation, although blocked their motor asymmet-
ries induced by amphetamine [20].
The neurotensin (NTS)-polyplex is a promising alter-
native to viral vectors to be used in gene therapy for PD
[21]. The NTS-polyplex consists of nanoparticles result-
ing from compaction of a plasmid DNA (pDNA) by the
electrostatic binding of a karyophilic peptide (KP) and
the NTS-carrier, which is a conjugate of poly-L-lysine,
NTS and a fusogenic peptide (FP) [22–24]. The NTS
carrier enables the delivery of genetic cargo to DA
neurons via NTS receptor type 1 (NTSR1) internaliza-
tion [25–28]. The inclusion of the human DA-
transporter (hDAT) gene promoter in the NTS-polyplex
provides a second point of selectivity to transgene ex-
pression in vivo [21, 24]. In a rat model of PD, the intra-
nigral transfection of NTS-polyplex harboring the
human glial-cell derived neurotrophic factor (hGDNF)
gene caused structural and functional restoration of
nigrostriatal pathway that correlated with the hemipar-
kinsonism remission [29]. These results indicate that the
transfection of neurotrophic genes into DA neurons is
the correct strategy to simultaneously affect their soma
and terminals [21]. On this basis, we propose that BDNF
overexpression in surviving DA neurons in the early
stage of Parkinsonism will prevent the nigrostriatal de-
terioration. To test this hypothesis, a single dose of
NTS-polyplex harboring the BDNF-flag transgene under
the control of hDAT (aka SLC6A3) gene promoter se-
quence was injected into the SN of hemiparkinsonian
rats at week one after a 6-OHDA injection into the ipsi-
lateral striatum. We showed that in a 6-OHDA-induced
early hemiparkinsonism, surviving DA neurons conserve
the expression of NTSR1 on cell bodies and neurites
that enabled gene transfection by NTS-polyplex. Two
weeks after transfection, the residual DA neurons
expressed BDNF-flag, which was accompanied by a sig-
nificant sprouting of DA fibers within the SN and partial
restoration of both innervation and dopamine levels in
the striatum, as well as a significant improvement of
motor behavior. Since residual DA neurons in PD pa-
tients still conserve levels of NTSR1 [30–32] and TrkB
[10], the NTS-polyplex-mediated BDNF gene therapy
might be feasible and useful in the early stage of PD.
Methods
Plasmids
The plasmid phDAT-BDNF-flag (10.5 kbp) coding for
BDNF-flag under the control of hDAT gene promoter
was obtained from cloning 868 bp of the BDNF-flag
coding sequence into Not I-Sal I sites of phDAT-EGFP
[24, 33].
The plasmid phDAT-EGFP (10.45 kbp) coding for en-
hanced green fluorescent protein (GFP) under the con-
trol of hDAT gene promoter was obtained from cloning
6250 bp of the 5′-flanking regulatory region of the
hDAT promoter into Eco47 III-Bgl I sites of pEGFP-N1
(Clontech; Palo Alto, CA, USA) [24, 33, 34].
Synthesis of the neurotensin carrier and polyplexes
The detailed procedures of NTS-carrier synthesis and of
NTS-polyplex formation at an optimum molar ratio are re-
ported elsewhere [24, 27, 35]. Briefly, NTS (Sigma-Aldrich;
Saint Louis, MO, USA) and FP (GLFEAIAEFIEGGWE
GLIEGCAKKK; purity > 90 %; SynPep; Dublin, CA, USA)
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were cross-linked with poly-L-lysine (48 kDa mean mo-
lecular mass; Sigma-Aldrich; Saint Louis, MO, USA) using
LC-SPDP (Thermo Scientific Pierce; Rockford, IL, USA) as
the cross-linker [35]. Suitable gel-filtration chromatog-
raphy was used to purify the SPDP-derivatives and the
NTS-SPDP-(FP-SPDP)-poly-L-lysine conjugate, the NTS
carrier. This conjugate was concentrated to 1 mL, further
dialyzed against phosphate-buffered saline solution, pH 7.4
(PBS), and sterilized by filtration.
The NTS-polyplexes were made by electrostatically
binding the mutant Vp1 SV40 KP (MAPTKRKGSCPGA
APNKPK; 90 % purity; Synpep Corp., Dublin, CA, USA)
to pDNA [24, 27, 35]. Retardation and retention gel as-
says were used to determine and calculate the optimal
molar ratio of NTS-polyplex components as described
in detail elsewhere [22, 24, 25, 27, 35]. Accordingly, the
final optimum molar ratio of NTS-polyplex components
for all the plasmids used were 30 nM pDNA: 20 μM KP:
720 nM NTS-carrier and, at this molar ratio, the con-
centration of NTS used was 720 pmol/μL, calculated as
per 125I-NTS [23, 24]. Based on the concentration and
size of pDNAs, the total amount of pDNA injected was
624 ng/3 μL for the phDAT-BDNF-flag and 618 ng/3 μL
for the phDAT-EGFP.
Experimental animals and stereotaxic surgery
All procedures were in accordance with the Mexican
current legislation, NOM-062-ZOO-1999 (SAGARPA),
based on the Guide for the Care and Use of Laboratory
Animals, NRC. The Institutional Animal Care and Use
Committee approved our animal use procedures (proto-
col # 0109–02). All efforts were made to minimize ani-
mal suffering.
Deeply anesthetized male Wistar rats (body weight 210–
230 g) were fixed on a stereotaxic apparatus (Stoelting;
Wood Dale ILL, USA). After trepanation, 3 μL of either
free base 6-OHDA (6.6 μg/μL in PBS containing 0.2 % as-
corbic acid; Sigma-Aldrich; St Louis, MO) or PBS (sham
lesion) were injected into the left striatum at 0.25 μL/min
flow rate in the coordinates AP, 0 mm from bregma; ML, +
4 mm from midline, DV, −5.2 mm from the dura mater
[36]. The transfection was made in the ipsilateral SN at the
coordinates AP, − 5.4 mm from bregma; ML, + 1.5 mm
from midline, DV, − 6.8 mm from dura mater [37]. Three
microliters of either NTS-polyplex or DMEM (sham trans-
fection referred to as DMEM) were injected at a flow rate
of 0.1 μL/min [37].
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
RT-PCR was used to show BDNF-flag, NTSR1, GFP, and
actin (housekeeping gene) mRNA expression in the trans-
fected SN following the extraction method and the retro-
transcription protocol as described previously [37]. To
amplify a 163 bp fragment of BDNF-flag, the forward pri-
mer was 5′-GCAATGCCGAACTACCCAATC-3′, and
the reverse primer was 5′- CTTGTCATCGTCGTCC
TTGTAGTC-3′. To amplify a 537 bp fragment of NTSR1,
the forward primer was 5′-CGTAAAGACCTCTATGC
CAA-3′ and the reverse primer was 5′- ACCTCCTGT
TGCTGATCCAC-3′. To amplify a 608 bp fragment of
GFP, the forward primer was 5′-CTGGTCGAGCTG
GACGGCGAC-3′ and the reverse primer was 5′-AGAG
TGATCCCGGCGGCGGTC-3′. To amplify 349 bp frag-
ment of actin, the forward primer was 5′-CGTAAAGAC
CTCTATGCCAA-3′ and the reverse primer was 5′-
ACTCCTGCTTGCTGATCCAC-3′. After an initial de-
naturation at 94 °C for 5 min, amplification was made with
35 cycles for BDNF-flag, GFP and actin and 40 cycles for
NTSR1 as follows: denaturation, 94 °C for 1 min, anneal-
ing, 60 °C for NTSR1 and actin, 63 °C for BDNF-Flag or
66 °C for GFP; extension, 72 °C for 30 s for BDNF-Flag,
36 s for GFP and actin and 45 s for NTSR1. PCR products
were analyzed by 1.5 % agarose gel or 5 % polyacrylamide
gel (BDNF-flag) electrophoresis, stained with ethidium
bromide, and photographed with a Kodak DC290 camera.
Amplification of their respective plasmids at same condi-
tions was maintained as a positive control.
Immunostaining
The presence of the NTSR1 and expression of the BDNF-
flag or GFP in tyrosine hydroxylase (TH) + nigral neurons
were shown by double immunofluorescence techniques
using the procedure described elsewhere [24, 29]. The pri-
mary antibodies were a rabbit anti-TH (1:300 dilution;
Chemicon; Temecula, CA), a mouse anti-flag (1:400 dilu-
tion; Sigma-Aldrich; St. Louis, MO, USA) and a mouse
anti-GFP (1:400; Sigma-Aldrich; St. Louis, MO). The sec-
ondary antibodies were a goat anti-rabbit FITC (1:400 di-
lution; Jackson ImmunoResearch Laboratories Inc.; West
Grove, PA, USA) and a donkey anti-mouse TRITC (1:400
dilution; Jackson ImmunoResearch Laboratories Inc.;
West Grove, PA, USA). The detection of the NTSR1 in
TH+ neurons was made using a mouse monoclonal anti-
TH (1:400; Sigma-Aldrich; St. Louis, MO, USA) and a
goat polyclonal anti-NTSR1 (1:400; Sigma-Aldrich; St.
Louis, MO, USA). The secondary antibodies were a don-
key anti-mouse IgG-FITC (1: 500; Jackson Immunore-
search; West Grove, PA, USA) and a Texas red rabbit
anti-goat IgG (1:500; Vector Laboratories; Burlingame,
CA, USA). For qualitative illustrations of transgene ex-
pression, fluorescence labeling was detected by a multi-
spectral confocal laser-scanning microscope (TCS-SPE,
Leica; Heidelberg, Germany) at excitation-emission wave-
lengths of 488–522 nm (green channel) and 568–635 nm
(red channel). For quantitative analysis, a Leica DMIRE2
microscope was used to detect the fluorescence at
excitation-emission wavelengths of 488–522 nm (green
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for FITC) and 568–585 nm (red for TRITC and Texas
red) and the immunohistochemical labeling with bright
field illumination. The images were digitalized with a
Leica DC300F camera (Nussloch, Germany) and proc-
essed using the v.1.46r ImageJ program (National Insti-
tutes of Health; Bethesda, MD) in the automatic counting
mode. Transfection efficiency was expressed as percentage
of flag or GFP expression with respect to the total TH+
cells (n = 3 rats per each experimental condition). TH-
immunohistochemistry was made in 10 slices taken every
120 μm from SN and striatum per rat (n = 4 rats per ex-
perimental group) using a monoclonal mouse anti-TH
(1:1000; Sigma-Aldrich; St. Louis, MO, USA), a biotinyl-
ated horse anti-mouse IgG (H + L) (1:200), and a VectaS-
tain Elite ABC kit with 3,3′-diaminobenzidine (Vector
Laboratories; Mexico City, Mexico) as reported previously
[29, 38]. SN slices were counterstained with Cresyl Violet
as reported previously [38]. The digitalized images of TH-
immunohistochemistry were processed using the v.1.46r
ImageJ program. The background intensity was detected
in an area without immunohistochemical staining and
eliminated from the measurements. To count mostly TH-
immunoreactive cells, 2 to 3 micrographs per slice were
taken using a 20x objective (total = 25 to 30 micrographs
of each SN per experimental condition) and only those
darkly stained neurons located lateral to a line that divides
the cerebral peduncle from the interpeduncular space on
each side were considered [39]. The mean intensity of
TH-immunoreactivity was determined in fibers and cells
in the SN and only in fibers in the striatum (4 representa-
tive levels per nucleus per experimental condition; n = 4
rats), and expressed as pixel counts.
HPLC analysis
DA content was determined in supernatants from homog-
enates of the SN or striatum using reverse-phase high pres-
sure liquid chromatography (HPLC) and electrochemical
detection, as described elsewhere [29, 38, 40]. Briefly, tissue
samples were homogenized in 0.1 M HClO4 containing 3,
4-dihydroxybenzylamine hydrobromide (50 μg/μL) at a
weight/volume ratio of 1:5 for SN and 1:10 for striatum.
Homogenates were centrifuged in a Beckman Airfuge
ultracentrifuge (Beckman Coulter, Inc.; Brea, CA, USA) at
10 psi for 15 min at room temperature, and then superna-
tants were filtered through 0.22 Millex-GV syringe filters
(Merck Millipore; Mexico City, Mexico). Using a Rheodyne
injector valve (Model 7125), 5 μL of filtrated supernatants
were injected into a Velosep RP-18 reverse-phase column
(3 μm, 100 × 3.2 mm; PerkinElmer; Waltham, MA, USA)
heated at 30.5 °C. The mobile phase buffer was 25 mM
NaH2PO4, 50 mM Na-Citrate, 0.03 mM EDTA, 10 mM
diethylamine HCl, 2.2 mM Octylsulfonic acid/sodium salt
(pH 3.2). One liter of the buffer was mixed with 30 mL of
methanol and 22 mL of dimethylacetamide to form the
mobile phase that was delivered by a BAS HPLC PM-80-
Pump (Bioanalytical Systems; West Lafayette, IN, USA) in
isocratic elution mode at 0.5 mL/min. The oxidation po-
tential of the glassy carbon electrode was set by a LC-4C
electrochemical detector at +0.75 V with respect to the
Ag/AgCl reference electrode (Bioanalytical Systems; West
Lafayette, IN, USA). Chromatograms were recorded and
analyzed by using ChromGraph® 2.34.00 REPORT 2.30©
software of Bioanalytical Systems, Inc. The pellets were re-
suspended in 120 μL of 0.1 M NaOH for protein deter-
mination using the Coomassie Plus assay kit (Pierce
Biotechnology Rockford; IL, USA) as reported elsewhere
[29, 38, 40]. Dopamine content was expressed as pg DA/μg
protein.
Behavioral testing
The spontaneous motor activity in a new environment
was measured using a black-painted wooden square box
(60-cm width and 50-cm height per wall) [41]. The con-
trol and experimental animals were placed individually in
the middle of the box and their motor activity was re-
corded for 30 min. The motor analysis was made using a
video image analyzer (Videomex-V, Columbus Instru-
ments; Columbus, OH, USA) at 3-min intervals using the
variables: distance traveled, walking time, resting time,
and stereotypic movements (short repetitive nondisplacing
movements such as scratching, grooming, and head shak-
ing). To prevent the animals from learning, this test was
made only once at one week after the lesion made with 6-
OHDA or the sham striatal injection and at two weeks
after the BDNF-flag, GFP or sham DMEM transfections.
To avoid residual drug effects, the behavioral testing was
made before the evaluation of the drug-generated behav-
iors. All behavioral assays were made during the light
phase between 10 h and 14 h as reported by previous
works [41–44].
The circling behavior was assessed as described previ-
ously [29, 37, 38]. Two treatments were used to generate
circling behavior; 1) Intraperitoneal injections of amphet-
amine (8 mg/kg; diluted in 1 mL of saline solution; Sigma-
Aldrich; St. Louis, MO) at 8 days and 23 days postlesion,
and 2) Subcutaneous injections of apomorphine (0.5 mg/kg;
diluted in 1 mL of saline solution; Sigma-Aldrich; St.
Louis, MO, USA) tested at 9 days and 24 days postlesion.
The circling behavior was monitored for 90 min and the
records were collected automatically. Only those animals
that showed ≥ 1,000 total turns in the amphetamine test
were considered for transfection with the phDAT-BDNF-
flag and phDAT-EGFP or sham transfection (DMEM).
Statistical analysis
All values are expressed as the mean ± SE. The statistical
differences were analyzed using GraphPad Prism 4 (San
Diego, CA, USA). A one-way ANOVA and Bonferroni’s
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multiple comparisons post hoc test were used to com-
pare the open field and cell counting results from differ-
ent treatments. A nonparametric Kruskal-Wallis test and
Dunns multiple comparison post hoc test were used to
compare the results for amphetamine and apomorphine
among all the groups. The accepted significance was at
P < 0.05.
Results
Residual DA neurons conserve NTSR1 in early
hemiparkinsonism
One week after the 6-OHDA lesion (early hemiparkin-
sonism), a reverse transcription-polymerase chain reac-
tion (RT-PCR) analysis showed the expression of NTSR1
mRNA in the SN with 6-OHDA lesion and in the posi-
tive controls (intact SN and N1E-115 cells), but not in
the negative controls (L929 cells and PCR reagents with-
out cDNA) (Fig. 1a). A confocal microscopy analysis
showed that NTSR1 immunoreactivity colocalized with
TH+ neuritric processes and cell bodies in the intact SN
(Fig. 1b). One week after the 6-OHDA lesion, the
number of neuritric processes and cell bodies with
double immunoreactivity to TH and NTSR1 showed a
significant decrease in the SN (Fig. 1b). These results in-
dicate that surviving DA neurons maintain the expres-
sion of NTSR1 protein thus facilitating the transfection
of transgene mediated by NTS-polyplex.
NTS-polyplex transfects DA neurons in early
hemiparkinsonism
To discriminate the BDNF-transgene expression from the
endogenous BDNF-gene product, a BDNF transgene la-
beled with the flag sequence was transfected with NTS-
polyplex in the ipsilateral SN one week after the 6-OHDA
lesion was made. Positive controls of transfections were
hemiparkinsonian rats transfected with phDAT-EGFP. At
week 2 after transfection, an RT-PCR analysis showed the
expression of BDNF-flag or GFP mRNA in the SN with 6-
OHDA lesion (Fig. 2a). On the contrary, neither the
untransfected, contralateral SN nor the two striatal nuclei
had BDNF-flag or GFP mRNA expression (Fig. 2a). At
week 2 after transfection, a confocal microscopy analysis
Fig. 1 NTSR1 mRNA and protein expression in the rat substantia nigra at the day of transfection (one week after a unilateral striatal 6-OHDA
lesion). a Representative photograph of RT-PCR amplicons showing NTSR1 expression. Actin was used as a control. Lane 1, N1E-115 cells
(positive control); lane 2, L929 cells (negative control); lane 3, intact SN (substantia nigra); lane 4, SN with lesion; lane 5, PCR reagents without
cDNA (internal control). b Representative confocal micrographs showing TH-immunoreactivity (IR) and NTSR1-IR in the mesencephalon of a
hemiparkinsonian rat. The control micrographs correspond to the intact SN contralateral to the side with the lesion
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of double-stained mesencephalon slices showed flag im-
munoreactivity in 94 ± 6 % of TH+ cells of hemiparkinso-
nian rats that were transfected with phDAT-BDNF-flag
(Fig. 2b and d). GFP immunoreactivity collocated with
67 ± 6 % of TH+ cells after transfection of phDAT-
EGFP (Fig. 2c and d). In contrast, no immunoreactivity
to flag or GFP was observed in the intact and untrans-
fected SN (Fig. 2b-d).
Structural recovery
Three weeks after the lesion, 6-OHDA decreased by
85 % the TH+ cell bodies (Fig. 3b-d, g-i, and p) and by
95 % their neuritic processes (Fig. 3b-d, l-n, and q) as
compared with the intact side (Fig. 3a, f, k). Two weeks
after BDNF-flag transfection (three weeks after the 6-
OHDA injection), the average number of surviving TH+
cells was similar to those counted in the groups with
GFP transfection, sham transfection (DMEM injection),
or without transfection (NT) (Fig. 3p). Regardless, a 7-
fold increase in TH+ fibers was detected within the
boundaries of the SN transfected with phDAT-BDNF-
flag (Fig. 3e, o, and q) as compared with the other three
negative controls (Fig. 3b-d, l-n, and q).
In the striatum, the 6-OHDA injection reduced by 90 ±
3 % the TH+ axon density, which was not modified by
GFP transfection or DMEM injection (Fig. 4b-d, g-i and k).
On the contrary, a 5-fold increase of TH+ fibers in the
striatum of hemiparkinsonian rats was detected when
Fig. 2 Transgenic expression in substantia nigra (SN) of hemiparkinsonian rats at week 2 after transfection using NTS-polyplex. a Representative
photograph of RT-PCR amplicons showing BDNF-flag and GFP expression. Actin was used as a control. Lane 1, plasmid phDAT-BDNF-flag or phDAT-EGFP
(positive control); lane 2, PCR reagents without cDNA (internal control); lane 3, SN (substantia nigra) with lesion and transfected with phDAT-BDNF-flag or
phDAT-EGFP; lane 4, contralateral SN without lesion and transfection; lane 5, striatum ipsilateral to the side with lesion and nigral transfection; lane 6,
contralateral striatum. Representative confocal micrographs showing TH-immunoreactivity (IR) and flag-IR (b) or green fluorescent protein (GFP)-IR (c) in
the substantia nigra (SN) of hemiparkinsonian rats. The control side are micrographs of the intact SN contralateral to the side with the lesion and
transfection (Experimental side). d Graph showing the percentage of flag or GFP expression with respect to the total TH+ cells. n= 3 rats per each
experimental condition. One-way ANOVA and Bonferroni post hoc test. *** P< 0.0001
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compared with the other three negative controls at two
weeks after phDAT-BDNF-flag transfection using NTS-
polyplex (Fig. 4e, j and k).
Dopamine level recovery
Three weeks after the 6-OHDA lesion, a significant 70 %
decrease of dopamine levels was measured in the stri-
atum and SN when compared with those in the intact,
contralateral side (Fig. 5a, b). Notably, two weeks after
transfecting the SN with the phDAT-BDNF-flag a 75 %
recovery of striatal DA levels was observed in compari-
son with the intact, contralateral striatum (Fig. 5a). DA
levels in the striatum was 5-fold higher than those in the
side with lesion and without transfection (NT), sham
transfection (DMEM injection), or GFP transfection
(Fig. 5a). However, no significant recovery of DA levels
occurred in the SN transfected with the phDAT-BDNF-
flag in comparison with the other control groups
(Fig. 5b).
Motor behavior recovery
Hemiparkinsonian rats exhibiting equivalent values of
circling behavior in 90 min (1216 ± 143 ipsilateral turns,
Mean ± SE, induced by methamphetamine and 103 ± 15
Fig. 3 Sprouting of TH+ fibers in the substantia nigra of hemiparkinsonian rats at week 2 after transfection with the phDAT-BDNF-flag using
NTS-polyplex. Representative micrographs of TH-immunohistochemistry and Cresyl Violet counterstaining (a-e) of the substantia nigra (SN) from
hemiparkinsonian rats at three weeks after a 6-OHDA striatal lesion, and two weeks after applying one of the following treatments in the
ipsilateral SN: without transfection (NT), Dulbecco’s Modified Eagle Medium injection (DMEM), phDAT-EGFP (GFP), or phDAT-BDNF-flag (BDNF)
transfection. Intact refers to the SN without striatal 6-OHDA lesion. Illustrations of image processing using ImageJ software for quantification of
the number of TH+ cells (f-j) and TH-immunoreactivity density (k-o). The bar graphs show the counting of TH+ cells (p) and TH-immunoreactivity
density (q) in the experimental conditions as mentioned above. Values are expressed as the mean ± SE; n = 3 animals per group. ** P < 0.001
when compared with the intact side. † P < 0.001 when compared with the negative control groups. One-way ANOVA with Bonferroni’s post hoc
test. Scale bar = 100 μm
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contralateral turns, Mean ± SE, induced by apomorph-
ine) received different treatments into the substantia
nigra one week after the ipsilateral-striatal 6-OHDA in-
jection. Two weeks after the lesion, the amphetamine-
induced circling behavior of negative control rats (NT,
DMEM and GFP) did not show statistical differences
when compared with that at week 1 after lesion (Fig. 6a).
Whereas, the apomorphine-induced circling behavior
significantly increased by more than 198 % in the groups
without transfection and in those with sham or GFP
transfections, suggesting hypersensitivity of dopamine
receptors (Fig. 6b). A significant reduction of both meth-
amphetamine- and apomorphine-induced circling behav-
iors occurred with transfection of phDAT-BDNF-flag
Fig. 4 Significant recovery of TH+ fibers in the striatum of hemiparkinsonian rats at week 2 after transfection with the phDAT-BDNF-flag using
NTS-polyplex. Representative micrographs of TH-immunohistochemistry of the striatum of hemiparkinsonian rats at three weeks after a 6-OHDA striatal
lesion, and two weeks after applying one of the following treatments in the ipsilateral substantia nigra: without transfection (NT), Dulbecco’s Modified
Eagle Medium injection (DMEM), phDAT-EGFP (GFP), or phDAT-BDNF-flag (BDNF) transfection(a-e. Illustrations of image processing using ImageJ software
for quantification of TH-immunoreactivity density (f-j). The bar graph shows TH-immunoreactivity density (k) in the experimental conditions as mentioned
above. Values are expressed as the mean ± SE; n= 3 animals per group. ** P< 0.001 when compared with the intact side. † P< 0.001 when compared
with the negative control groups. One-way ANOVA with Bonferroni’s post hoc test
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(Fig. 6). When compared with the circling behavior
of control hemiparkinsonian rats, the reduction in
methamphetamine-induced rotational behavior was 68 %
at week 2 after phDAT-BDNF-flag transfection, whereas
the reduction was 30 % for apomorphine-induced rota-
tional behavior at the same time (Fig. 6).
The spontaneous motor behavior of hemiparkinsonian
rats in an open-field test also showed recovery at two
weeks after the phDAT-BDNF-flag transfection. Accord-
ingly, the values of the four variables (distance traveled,
ambulatory time, resting time, and stereotypy time) mea-
sured in hemiparkinsonian rats with BDNF-flag transfec-
tion were not significantly different from those recorded
in rats with a false lesion (Fig. 7). In contrast, the values
of distance traveled, ambulatory time and stereotypy
time in the groups without transfection or DMEM injec-
tion (sham transfection) were significantly lower than
those registered in rats with a false lesion were. In the
group with GFP transfection, only the distance traveled
and ambulatory time showed significant decreases,
whereas stereotypy time did not differ from that mea-
sured in rats with a sham lesion. The values of resting
time showed a significant increase only in hemiparkin-
sonian rats without transfection or with sham transfec-
tion in comparison with the values recorded in animals
with a sham lesion (Fig. 7).
Fig. 5 Partial recovery of striatal DA levels at week 2 after transfection with the BDNF-flag gene into DA neurons using NTS-polyplex. DA levels
were measured using HPLC with electrochemical detection in the striatum (a) and in the substantia nigra (b) at three weeks after unilateral
microinjection of 6-OHDA in one striatum (experimental side), and at two weeks after applying one of the following treatments in the ipsilateral
substantia nigra: without transfection (NT), Dulbecco’s Modified Eagle Medium injection (DMEM), phDAT-EGFP (GFP), or phDAT-BDNF-flag (BDNF)
transfection. The SHAM lesion group was injected in the striatum only with PBS (6-OHDA vehicle). The control side refers to the intact tissues
(striatum or substantia nigra) contralateral to the side with the lesion and transfection. The experimental side refers to tissues ipsilateral to the
lesion and transfection. Values are expressed as the mean ± SE; n = 4 animals per group. * P < 0.05, ** P < 0.01 when compared with the values
caused by a sham lesion. † P < 0.05 when compared with the values of the untransfected side (NT). One-way ANOVA with Bonferroni’s post
hoc test
Fig. 6 Drug induced-circling behavior in hemiparkinsonian rats at two weeks after transfecting the substantia nigra using NTS-polyplex. One week
after a 6-OHDA striatal injection treatments were applied into the substantia nigra (arrow) as follows; without transfection, Dulbecco’s Modified
Eagle Medium injection (DMEM), phDAT-EGFP or phDAT-BDNF-flag transfection. Ipsilateral circling behavior was included by amphetamine
(8 mg/Kg, i.p.), whereas contralateral circling behavior was induced by apomorphine (0.5 mg/kg, s.c.) at weeks 1 (before treatment; n =28 animals)
and 3 weeks after the striatal 6-OHDA lesion; n = 4 for the NT group and n = 8 animals for the rest of the groups. * P < 0.05, when compared with
the values measured at week 1. † P < 0.05 when compared individually with the values of the other groups at week 3. Kruskal-Wallis test with
Dunns post hoc test
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Discussion
Our results show for the first time that the overexpres-
sion of BDNF within the DA neurons of the SN amelio-
rates the acute hemiparkinsonism induced by a striatal
injection of 6-OHDA in the rat. The ability of NTS-
polyplex to transfect genes into surviving DA neurons
[29, 45] was a key factor to increase their levels of BDNF
and thus strengthen its neurotrophic effects on the in-
jured nigrostriatal system. Our results showed that the
residual DA neurons of the SN still maintain the expres-
sion of NTSR1 and its ability to mediate the transfer of
GFP and BDNF-flag gene by NTS-polyplex. These re-
sults agree with the notion that NTS-polyplex enters DA
neurons through NTSR1 internalization to deliver its
genetic cargo to the cell nucleus and express the trans-
genic protein [21, 24, 27–29]. The expression of NTSR1
is not only maintained in experimental neurodegenera-
tion [46, 47], but also in PD patients in whom the pres-
ence of NTSR1 mRNA and protein has been clearly
demonstrated by ligand binding [30], autoradiography
[31], and in situ hybridization [32]. The presence of
NTSR1 in residual DA neurons opens up the possibility
of using the NTS-polyplex-mediated BDNF gene deliv-
ery as a therapy for PD.
The assertion that BDNF influences DA neurons
through autocrine and paracrine mechanisms has been
sustained by the finding that those neurons coexpress
BDNF and its TrkB receptor [1, 2]. In PD, the decreasing
levels of BDNF and TrkB accompanying the progressive
death of DA neurons inevitably lead to the loss of their
own neurotrophic source to halt the progress of neuro-
degeneration [9, 11]. Our results in an experimental rat
model of PD showed that strengthening of the neuro-
trophic source by BDNF transfection into surviving DA
neurons was able to partially rescue the functional in-
nervation of the nigrostriatal system. BDNF-flag expres-
sion caused a significant sprouting of DA fibers and
increased DA levels in the injured striatum as soon as
two weeks after transfection. Although significant
sprouting of DA fibers was also seen in the SN, the
number of DA neurons and DA levels in this nucleus
were not increased, suggesting that BDNF-flag expres-
sion does not stimulate neurogenesis but promotes
neuritogenesis in the SN and striatum. These results
support the inability of BDNF to enhance neurogenesis
in adult mice and rats [48] and its ability to stimulate
axonal elongation and dendritic branching in cell cul-
tures and in experimental animals [49–53]. Our results
about the lack of neurogenesis and the stimulation of
neuritogenesis also agree with previous studies in which
a BDNF gene was transduced by an AAV vector in the
SN [20] or BDNF protein was provided by epigenetically
Fig. 7 Spontaneous motor behavior of hemiparkinsonian rats in an open field at two weeks after transfecting the substantia nigra
using NTS-polyplex. SHAM refers to the group of rats with a false lesion. One week after a 6-OHDA striatal injection treatments were
applied into the substantia nigra as follows: without transfection (NT), injection with Dulbecco’s Modified Eagle Medium (DMEM), and
transfection with phDAT-EGFP (GFP) or phDAT-BDNF-flag (BDNF). Values are expressed as the mean ± SE; n = 8 animals per group.
** P < 0.01, *** P < 0.001 vs. SHAM. One-way ANOVA with Bonferroni’s post hoc test
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induced BDNF-secreting human mesenchymal stem cell
grafts [19]. Regardless, the partial recovery of striatal DA
innervation induced by BDNF-flag expression led to
substantial reversal of drug-induced motor asymmetry in
hemiparkinsonian rats. Even more striking, BDNF-flag
expression completely corrected the impairment of
spontaneous motor behaviors in hemiparkinsonian rats.
Those results indicate that the residual DA neurons keep
the responsiveness to BDNF and support the presence of
TrkB receptors on these neurons as recently shown [19].
Because TrkB mRNA expression has been shown in the
SN of PD patients, BDNF-gene therapy might be effect-
ive in the early stage of PD [10]. Clinical studies show
that the intensive rehabilitation treatment increases the
BDNF levels and improves PD signs in patients in the
early stages of the disease [54], and that there is a posi-
tive correlation between advanced stages of the disease
and serum levels of BDNF, may be as a potential com-
pensatory mechanism [55]. These results suggest that
BDNF treatment might be effective at any stage of the
disease. However, the use of other animal models differ-
ent from 6-OHDA or implementing chronic models
treated with BDNF is necessary to prove the feasibility
of BDNF as a treatment for PD.
Preclinical studies with GDNF [29, 56, 57], neurturin
[58], or BDNF as reported and shown in this study have
allowed gaining insight into the potential benefits of
gene therapy to restore the DA innervation in PD. How-
ever, this procedure has some limitations. For example,
those expressing GDNF have been associated with un-
desirable behavioral effects resulting from aberrant in-
nervation of the regenerating DA fibers [59] and the
decrease of DA synthesis [60]. Others have documented
a striatal DA hypofunction after a chronic intranigral ad-
ministration of BDNF [61]. These biosafety concerns
urge for more research devoted to identify the best vec-
tors and genes that provide the maximum benefits with
the minimum of adverse effects. In addition, the regula-
tion of neurotrophic gene expression must be imple-
mented in the gene vectors in order to switch off the
gene expression in the case of development of unex-
pected undesirable effects.
Although viral gene therapy for PD has been under
evaluation for a number of years [16, 62, 63], the availabil-
ity of alternate gene transfer methods remains important
considering the concerns with potential immune reactions
to viral vectors [64, 65] and potential oncogenicity of viral
vectors able to integrate the transgene into the host
genome [66, 67]. A recent study supports the lack of
inflammatory effect of systemically or locally injected
NTS-polyplex [22]. Moreover, the transfer of the cerebral
dopamine neurotrophic factor (CDNF) into DA neurons
via NTS-polyplex did not induce neuroinflammation in
vivo and additionally exerted an anti-inflammatory effect
in the 6-OHDA rat model of PD [45]. These results show
the safety of local injection of NTS-polyplex NPs and sus-
tain its possible application in the clinic. Recent studies in
PD patients demonstrate that the surgical approach to SN
is a feasible and safe procedure for viral gene transfer in
humans [68]. Nevertheless, invasive injection in the SN is
the major limitation of NTS-polyplex because is unable to
cross the blood–brain barrier (BBB) when injected intra-
venously [69]. To overcome this limitation, two methods
of safe administration can be used. The most promising
method is the reversible opening of the BBB using focused
ultrasound (FUS) that allows the targeted delivery of
nanoparticles in the order of micrometers in diameter
[70], and by their size (50–150 nm) [22–24], the NTS
polyplex nanoparticles can pass through the transient
opening of the BBB. The other method is the intrathecal
administration [71], which might allow the targeted gene
delivery of NTS-polyplex through the cerebrospinal fluid.
This application is feasible because NTS-polyplex enables
targeted gene delivery into cancer cells through the blood
stream as previously demonstrated in in neurobalstoma
and breast cancer animal models [23, 69].
Conclusions
Our results show that in a 6-OHDA-induced early hemi-
parkinsonism, surviving DA neurons conserve the ex-
pression of NTSR1 on cell bodies and neurites that
enabled gene transfection by NTS- polyplex. The
expressed BDNF-flag produced partial biochemical,
structural, and behavioral recovery from early parkinson-
ism. The major effect of BDNF-flag was on the DA
branching in the striatum and SN. The lack of effect on
the cell number might be accounted by the inability of
BDNF to stimulate subventricular zone neurogenesis in
adult mice and rats [48]. Regardless, BDNF gene therapy
can be associated to other neurogenesis-stimulating
treatment to reinforce the sprouting of new DA terminals
and provide maintenance of their synaptic connectivity.
The results of our work and the success of preclinical
studies with other neurotrophic genes strongly support
the feasibility of using the NTS-polyplex in gene therapy
for an efficient and selective recovery of striatal DA in-
nervation in the early stages of PD [50].
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